NFKB1 and COVID-19: Xiyanping injection inhibits the extracellular MAPK inflammatory pathway (inhibition of MAPK1, MAPK3, inhibition of MAP production), inhibits NF-κB and other pathways in the nucleus through various pathways, inhibits the release of various inflammatory factors, and plays a role in the treatment of COVID-19.